

**SPECIAL ARTICLE**

# Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment<sup>†</sup>

A. Fabi<sup>1</sup>, R. Bhargava<sup>2</sup>, S. Fatigoni<sup>3</sup>, M. Guglielmo<sup>4</sup>, M. Horneber<sup>5</sup>, F. Roila<sup>3</sup>, J. Weis<sup>6</sup>, K. Jordan<sup>7</sup> & C. I. Ripamonti<sup>4</sup>, on behalf of the ESMO Guidelines Committee\*

<sup>1</sup>Division of Medical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy; <sup>2</sup>William Osler Health System, Corporate Department of Research, Department of Oncology and Division of Palliative Care, Brampton, Canada; <sup>3</sup>Division of Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia; <sup>4</sup>Oncology-Supportive Care Unit, Department Onco-Haematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; <sup>5</sup>Department of Internal Medicine, Division of Oncology and Hematology & Division of Pneumology, Paracelsus Medical University, Klinikum, Nuremberg; <sup>6</sup>Department of Self Help Research in Oncology, Comprehensive Cancer Center, University Medical Center, Freiburg; <sup>7</sup>Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

Available online 12 March 2020

**Key words:** cancer-related fatigue, Clinical Practice Guidelines, diagnosis, treatment

## INTRODUCTION

Fatigue is the most common symptom experienced by patients during the cancer trajectory from diagnosis to the end of life and is defined as a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent physical activity and that interferes with usual functioning.<sup>1,2</sup> Cancer-related fatigue (CRF) is different from other types of fatigue by its severity and persistence and the inability to alleviate it through rest or sleep. CRF affects almost 65% of patients with cancer; over two-thirds of these patients describe CRF as severe for at least 6 months and one-third reports this as persistent fatigue for a number of years after treatment.<sup>3–5</sup> Up to 40% of patients report fatigue at cancer diagnosis, 80%–90% during chemotherapy (ChT) and/or radiotherapy (RT), in particular 17%–21% during ChT alone and 33%–53% during association of ChT and RT.<sup>2,3</sup> Moreover, hormonal therapy, targeted therapy and also immunotherapy can be responsible for fatigue. CRF related to immunotherapy has an incidence from 12% to 37% up to 71% when immunotherapy is combined with ChT, monoclonal antibodies, antiangiogenic agents and targeted therapies. In addition, immunotherapy can be a cause of fatigue when it is complicated by endocrinological disorders.<sup>6,7</sup>

The aetiology of CRF has not yet been thoroughly elucidated, although it may involve several physiological and

biochemical systems which, in turn, might vary according to the type of tumour, stage of disease and treatment.<sup>1,3,8</sup>

CRF probably starts in the skeletal muscles due to a progressive reduction of physical activity (sometimes with physical interruption), but the brain is also critical as a central regulator of fatigue perception. Recently, tryptophan degradation and several cytokines and other pro-inflammatory mediators produced in response to cancer have been associated with fatigue; however, their direct role in pathogenesis of fatigue is controversial. Cytokines have been implicated in the pathophysiology of fatigue by possibly acting at multiple levels, including mood, muscle mass, strength and metabolic status. A recent review showed a positive correlation between fatigue and circulating levels of inflammatory markers; interleukin (IL)-6, IL-1 and neopterin values, in particular, were significantly associated with CRF.<sup>1,3,8</sup>

## GENERAL PRINCIPLES OF CARE

Shared decision-making between the fatigued cancer patient and health care professionals (oncologists and specialised nurses when available) should take place during diagnosis and all phases of care [II, B].

The health care professional should:

- acknowledge the reality and impact of the condition and the symptoms;
- provide information on the possible causes, nature and course of CRF;
- provide information about the range of interventions and management strategies available to the patient;
- take into account the person's age, the severity of their fatigue, their preferences and experiences and the outcome of previous treatment(s) by means of a careful assessment on a regular basis;

\*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Geneva 4, 6900 Lugano, Switzerland  
E-mail: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org) (ESMO Guidelines Committee).

<sup>†</sup> Approved by the ESMO Guidelines Committee: February 2020.  
0923-7534/© 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

- offer information about support groups for people with fatigue and their carers, if available.

## DIAGNOSIS


In the last two decades, progress has been made in the understanding of CRF including its measurement in adults and children, but a specific diagnostic algorithm is not yet well defined.<sup>9</sup> In an effort to address what constitutes CRF, specific diagnostic criteria were developed and proposed for inclusion in the International Statistical Classification of Diseases and Related Health Problems 10th edition (ICD-10).<sup>10,11</sup> The criteria define CRF as a syndrome by the presence of the following specific symptoms: diminished energy, increased need to rest (which is disproportionate to changes in activity level) and related symptoms across physical, emotional and cognitive domains. The symptoms must have persisted for or recurred during a defined period of time and caused significant distress or impaired social, occupational or other important areas of functioning. The symptoms are believed to be a result of the malignant disease or its therapy. The presence of an active psychiatric

comorbidity such as a major depressive disorder or diseases requiring prophylactic medication that could explain the state of fatigue are excluded from the classification of CRF.<sup>10,11</sup> Although the findings of a systematic review support the reliability and validity of the diagnostic criteria for a CRF diagnosis,<sup>12</sup> further rigorous validation is needed.<sup>9</sup>

## SCREENING AND RISK ASSESSMENT

Given the prevalence of CRF and its impact on functioning of cancer patients and their overall quality of life (QoL), as well as adherence to treatment, there is accordance among guidelines that cancer patients should be screened for the presence of symptoms of fatigue. Screening should occur as part of a holistic needs assessment, at regular intervals during therapy and aftercare, and, whenever possible, be performed by a clinical nurse specialist.

Due to the overlapping of CRF with depression, differential diagnosis must be made with validated instruments.<sup>13</sup> Further assessment should follow a positive screen for fatigue.<sup>1,14–16</sup> The recommended approach for screening and for diagnostic assessment is shown in Figure 1.



**Figure 1. Practical assessment of CRF.**

ChT, chemotherapy; CRF, cancer-related fatigue; NRS, numerical rating scale; RT, radiotherapy.

<sup>a</sup> Urinalysis for protein, blood and glucose, full blood count, urea and electrolytes, liver function, thyroid function, erythrocyte sedimentation rate, C-reactive protein, blood glucose, serum creatinine.

<sup>b</sup> For example, hypothyroidism, hypogonadism, adrenal insufficiency and hypopituitarism, especially in patients receiving immunotherapy.

<sup>c</sup> Only for short-term use in metastatic cancer patients.

As a subjective experience, CRF is measured most efficiently via self-report, and a recent analysis suggests that a 10-point numerical rating scale (NRS) for fatigue is the best screening tool.<sup>16</sup> There is an agreement that fatigue intensity is graded as mild, with scores of 1–3, moderate as 4–6 and severe as 7–10.<sup>17</sup> However, as fatigue often occurs with associated symptoms, a screening tool that captures multiple symptoms may also be of clinical value and could help to identify patients who could significantly benefit from targeted symptom management.<sup>14</sup>

Patients with similar fatigue intensity may have widely divergent levels of disability. Therefore, screening for symptoms of fatigue should also evaluate the ability to carry out daily activities. The NRS is simple and immediate, but when the score reaches 4, it is necessary to use a more specific questionnaire, such as the Brief Fatigue Inventory (BFI), which integrates the assessment of fatigue severity and its impact on important functional domains.<sup>18</sup> The BFI has proved to be a reliable and easy-to-understand questionnaire, validated in many languages, in clinical screening and in research.<sup>18</sup>

Regardless of which screening tool is used, there is a need for comparable data to reliably detect changes over time.

For research purposes, several instruments measuring fatigue have been developed.<sup>19</sup> Many of these instruments take into account the multifactorial nature of fatigue and meet accepted standards of validity and reliability. They are based on the conceptualisation of fatigue as a subjective experience, which is comparable to other symptoms: it is what the person experiencing it says it is. At the moment, there is no clear recommendation regarding the most appropriate subjective measure. Most recently, the multi-dimensional QoL questionnaire (QLQ-FA12) module has been developed and evaluated following the methodological guidelines of the European Organisation for Research and Treatment of Cancer (EORTC).<sup>20,21</sup> [Supplementary Table S1](#), available at *Annals of Oncology* online, shows a sample of specific instruments that have reasonable reliability and are validated in cancer patients.

All patients identified with moderate to severe intensity of fatigue through screening should undergo a diagnostic assessment with the aim of identifying contributing and comorbid conditions that require treatment.<sup>1,14,15</sup> This assessment should include a focused fatigue history, a thorough medical examination, an evaluation of the status of the underlying malignant disease, a review of body systems, a mental status examination and laboratory blood tests (see [Figure 1](#)).

As part of the diagnostic assessment, the oncologist should consider contributing factors requiring treatment (e.g. pain, emotional distress, anaemia, active infection, malnutrition and thyroid, renal, cardiovascular and pulmonary disease), and such that require evaluation over time to determine the extent to which they contribute to CRF (e.g. effects of medications, unstable diabetes mellitus, infection, sleep pattern disorders including restless leg syndrome and periodic limb movement, chronic organ dysfunctions,

neurological disorders and activity levels). To rapidly and sensitively screen for comorbidities or contributing depressive disorders in clinical practice, the two-question test could be of help<sup>22</sup>:

- In the last month, have you often felt dejected, sad, depressed or hopeless?
- In the last month, did you experience significantly less pleasure than usual with the things you normally like to do?

Furthermore, fatigue symptoms should be reviewed with specific attention to social and environmental contributors.

Although predictive values of laboratory tests are low in CRF, some parameters should also be considered ([Figure 1](#)). A thorough clinical evaluation establishes the ‘phenotype’ of the individual patient’s fatigue, which helps to sharpen the thinking about underlying mechanisms and tailoring of treatment or referral to an appropriately trained professional. As part of the process of guideline implementation, it should be determined who is responsible for screening and for initiating subsequent assessment if indicated.

### Recommendations

- All cancer patients should be routinely screened for the presence and severity of fatigue from the point of diagnosis onward, at regular intervals during therapy and aftercare and if clinically indicated [II, B].
- Screening should be done using brief and validated tools with established cut-off values for severity (e.g. NRS) [II, B].
- Patients who screen positively for fatigue (values of 4 out of 10 or higher indicating moderate to severe fatigue) should undergo a comprehensive and focused diagnostic assessment, with the aim to identify treatable contributing and comorbid conditions [II, B].
- The diagnostic assessment should involve a focused fatigue history, a thorough medical examination, a status of the underlying malignant disease, a review of body systems, a mental status examination and a minimum battery of laboratory tests [II, B].

## MANAGEMENT

### Physical exercise

Systematic reviews and meta-analyses focusing on the role of physical exercise in patients with cancer during active treatment have documented an improvement in domains such as CRF, physical and muscular strength, activity levels and aerobic fitness.<sup>23,24</sup> There is growing evidence that physical exercise can attenuate systemic inflammation and improve CRF, allowing patients with or without cachexia to become more capable of carrying out the activities of daily living (ADLs) and thereby to improve the functional QoL.<sup>25</sup> Despite significant evidence for exercise in the management of CRF, an exact exercise prescription for patients with CRF does not exist. Current exercise prescription guidelines focus broadly on the general well-being of patients with

cancer, encouraging 150 min/week of aerobic exercise, 2 days/week of strength training and flexibility exercises on days when aerobic or resistance exercise is not carried out.<sup>26</sup> Some observational and interventional studies have also suggested that patients with cancer who engage in at least 3–5 hours of moderate activity weekly may experience better outcomes and have fewer side-effects of anti-cancer therapy, including CRF.<sup>23</sup>

**Type of physical exercise.** Exercises of moderate intensity include brisk walking (5 km/h), stationary bike with light effort and home-based exercises.<sup>27</sup> There has been a growing interest in using physical exercise as a supplementary treatment modality, with increasing research in patients at various stages of their cancer trajectory. In patients with cancer, during and post-treatment, prolonged inactivity and lack of exercise may lead to loss of skeletal muscle mass and strength, which gradually affects their ability to carry out simple ADLs (e.g. walking up the stairs or maintaining body balance). This ‘deconditioned’ state of the body can lead to the occurrence of physical ailments, decreased muscle strength and cardiovascular fitness, low self-esteem and an increase in anxiety and depression. ‘Reconditioning’ can be achieved through a structured exercise programme designed to increase a patient’s skeletal muscle mass and strength, thereby also improving the QoL of these patients.<sup>28</sup>

Moderate-intensity resistance training is documented as safe by randomised controlled trials (RCTs) and has been shown to decrease blood lipids, optimise immune activity and promote an anti-inflammatory state in patients with cancer.<sup>29,30</sup> Another RCT in non-cachectic patients with cancer<sup>31</sup> has revealed that resistance training significantly improved self-esteem, muscular strength and lean body mass. A resistance exercise programme may also increase muscle strength and maintain patients’ functional ability.<sup>32</sup> A meta-analysis of 44 studies including 3254 patients with cancer concluded that moderate-intensity resistance exercise reduced fatigue.<sup>33</sup> Another meta-analysis of 70 studies, including 4881 patients with cancer during or after treatment, suggested that exercise can reduce CRF by a mean effect of 0.32 [95% confidence interval (CI), 0.21–0.43] and 0.38 (95% CI 0.21–0.54) during and after cancer therapy, respectively. Muscle strength and better physical functioning were also shown to be significantly greater in patients undergoing moderate- to high-intensity combined resistance and aerobic exercise.<sup>34</sup> Aerobic exercise utilises large muscle groups for prolonged periods of time. Examples of aerobic exercises include walking, running, cycling and swimming. A 2012 Cochrane analysis included 56 randomised trials ( $n = 4826$ ), 36 of which were conducted among participants undergoing active cancer treatment. Exercise resulted in a decrease in fatigue from baseline to 12 weeks’ follow-up.<sup>25</sup>

Based on current knowledge and the results of multiple RCTs and systematic reviews,<sup>35,36</sup> physical exercise can be recommended in non-cachectic patients with cancer.

Aerobic, resistance and moderate physical exercises are recommended in patients with CRF because they provide symptomatic relief in depression, anxiety, pain and improve muscle strength.

Walking can also be recommended in non-cachectic patients with cancer as the main type of physical activity carried out (minimum of 2–3 times/week, 30–60 minutes, perceived as moderately strenuous), although cycling or more vocational forms of activity (e.g. heavy housework or gardening) can be done as long as they provoke the desired level of response on exertion. It has been documented that home-based walking at a moderate intensity (50%–70% of maximum heart rate), carried out for 10–45 minutes daily, 4–6 days weekly for 1–6 months, during ChT and RT for breast cancer reduced CRF, sleep disruption, depression and anxiety while improving cardiopulmonary function and QoL in non-cachectic patients with cancer.<sup>37</sup> A systematic review of patients with cancer showed that aerobic exercise and resistance exercise are superior to no exercise for improving patient-reported physical functioning in cancer patients receiving treatment. This systematic review demonstrated that aerobic and resistance exercises improve upper and lower body muscle strength more than usual care.<sup>25</sup> A study focusing on the rest interval between sets in strength training<sup>38</sup> suggested that functional resistance exercises involving major muscle groups in the upper and lower body should be prescribed at least two to three times weekly. A more intense aerobic training includes 30–60 minutes of continuous or intermittent aerobic activity training (minimum of 10-minute bouts accumulated during the day) at 50%–90% of maximal heart rate.<sup>39</sup>

Systematic reviews and meta-analyses of patients with advanced cancer indicate that QoL benefits resulting from increased physical activity may vary with stage of cancer, treatment modality and the patient’s current lifestyle.<sup>25</sup> Improvement may be attributed to the exercise programmes, increased attention by health care personnel and perceived benefits from carrying out group activities with fellow patients. In the future, larger RCTs with a focus on study quality are required to explore the effect of physical exercise on the QoL of patients with advanced cancer.

### Recommendations

- Based on the results of RCTs and systematic reviews, physical exercise can be recommended in non-cachectic patients with cancer [I, B].
- Physical exercise of moderate intensity and aerobic and functional resistance exercise are recommended in patients with CRF [I, B].
- Physical activities like walking and home-based aerobic and resistance exercises are recommended to improve CRF and QoL [II, B].

### Pharmacological treatments

Several randomised, double-blind, placebo-controlled, phase II–III clinical trials evaluating drugs and nutraceutical interventions for CRF treatment have been carried out in oncological patients during all phases of disease.



Nevertheless, these studies present many limitations due to the variability in the enrolled patients and type of cancers, the type of interventions and the scales used to evaluate CRF.

**Psychostimulants.** The mechanism of action of psychostimulants is not completely known; they probably act as dopamine and norepinephrine reuptake inhibitors, increasing the level of dopamine in the central nervous system (CNS). Small open studies with psychostimulants suggest possible benefits in the control of CRF. Subsequently so far, 19 randomised, double-blind, placebo-controlled, phase II and III clinical trials have been published on the following psychostimulants:

- methylphenidate and dexmethylphenidate;
- long-acting methylphenidate;
- dexamphetamine;
- modafinil;
- armodafinil.

In all of these studies, the control of CRF was the primary end point and the fatigue score at entry was generally  $\geq 4$ .<sup>40–58</sup> For study details, see [supplementary Data](#), available at *Annals of Oncology* online.

In conclusion, 15 studies showed no superiority of the psychostimulants with respect to placebo, while four studies (three with methylphenidate and one with dexmethylphenidate) showed less fatigue with respect to placebo.<sup>43–45,48</sup> Furthermore, a subgroup analysis suggested a benefit in the control of severe fatigue in another two trials (one with long-acting methylphenidate and the other with modafinil).<sup>49,52</sup>

**Antidepressants.** Two studies evaluated the efficacy of paroxetine (a selective serotonin reuptake inhibitor known to modulate brain serotonin) in reducing CRF.

The first study was carried out in 704 patients undergoing ChT for different cancers (>50% breast cancer). Five hundred and forty-nine patients, reporting fatigue at the second cycle of ChT, were randomly assigned to receive oral paroxetine 20 mg daily or placebo for 8 weeks.<sup>59</sup> Fatigue was evaluated with the Fatigue Symptom Checklist questionnaire and no difference was detected in fatigue between the two groups. At the end of the study, there was a difference in the mean level of depression in favour of paroxetine.

In the second study, carried out in 94 breast cancer patients undergoing ChT, no difference was shown in the fatigue incidence or intensity between paroxetine 20 mg daily and placebo, while paroxetine reduced depression more than placebo.<sup>60</sup>

**Acetylcholinesterase inhibitors.** Donepezil, a long-acting selective acetylcholinesterase inhibitor, has been evaluated in a double-blind, placebo-controlled trial in 142 patients with advanced cancer (>50% breast cancer patients) and fatigue  $\geq 4$  as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and/or Edmonton Symptom Assessment Scale (ESAS), at a dose of 5 mg daily

for 7 days.<sup>61</sup> On day 8, the fatigue incidence improved significantly in both the donepezil and placebo groups, but no significant differences in efficacy and toxicity were shown between the two treatments.

**Corticosteroids.** Corticosteroids are frequently recommended in patients with metastatic cancer for the control of CRF based on the results of some studies showing an improvement in QoL. Two studies evaluated corticosteroids in CRF.

A double-blind, placebo-controlled study evaluated dexamethasone 4 mg twice a day (b.i.d.) for 14 days.<sup>62</sup> Eligible patients reported a fatigue score  $\geq 4$  with three or more CRF-related symptoms in the previous 24 hours measured by ESAS (pain, nausea, appetite lost, depression, anxiety or sleep disturbances). The primary end point was the change in fatigue scores measured by FACIT-F. Eighty-four patients entered the study. The mean improvement of fatigue at day 15 was significantly superior with dexamethasone compared with placebo. The rate of adverse events was not significantly different between the two treatments.

Another study evaluated the effects of methylprednisolone 16 mg b.i.d. versus placebo administered for 7 days on pain, fatigue and appetite loss in 50 patients with advanced cancer.<sup>63</sup> Patients receiving methylprednisolone experienced an improvement on the EORTC-QOL C30 questionnaire compared with the placebo group. Long-term steroid use should be avoided due to the possible side-effects.

**Other drugs.** Eszopiclone, a sedative hypnotic drug, has been evaluated in 45 inpatients without significant fatigue improvement.<sup>64</sup>

The progestin agent megestrol acetate has been evaluated in a randomised, double-blind, crossover study in 53 patients with advanced cancer.<sup>65</sup> In this study, in which the impact on anorexia was the primary end point, megestrol acetate ameliorated fatigue with respect to placebo.

No significant effect on CRF improvement was found with melatonin in a randomised, crossover study in 72 patients with advanced cancer in palliative care units.<sup>66</sup>

### Recommendations

- The use of modafinil and armodafinil is not recommended for the control of CRF [II, D].
- Concerning the use of methylphenidate, dexmethylphenidate, long-acting methylphenidate and dexamphetamine, the panel has not reached a consensus:
  - for three panel members, the psychostimulants could be considered in thoroughly selected patients and their usefulness and safety should be evaluated after a very short time period [II, C];
  - for the other six panel members, psychostimulants cannot be recommended, because most trials failed to show the intended effects on the primary outcome measures [II, D].
- The use of antidepressants, and in particular paroxetine, is not recommended for the control of CRF [II, D].
- The use of donepezil for the control of CRF is not recommended [II, D].

- Short-term use of dexamethasone or methylprednisolone is recommended for the control of CRF in metastatic cancer patients [II, B].
- The use of eszopiclone, megestrol acetate and melatonin is not recommended for the control of CRF [II, D].

### Nutraceutical treatments

**L-Carnitine.** A prospective double-blind, placebo-controlled study was carried out evaluating the role of L-carnitine administered at dose of 2 g daily for 4 weeks in 376 patients with advanced cancer and fatigue (evaluated with BFI).<sup>67</sup> Eighty-five percent of these patients were undergoing RT or ChT. In both groups of patients, there was an improvement for fatigue but no differences were shown between L-carnitine and placebo-treated patients, even in patients with a baseline deficiency of L-carnitine (33% of the enrolled patients).

A *post hoc* analysis of a double-blind, placebo-controlled study carried out in terminal cancer patients referring fatigue and L-carnitine deficiency showed that 1 g b.i.d. of L-carnitine supplementation ameliorated fatigue symptoms.<sup>68</sup>

**Coenzyme Q<sub>10</sub>.** A double-blind, placebo-controlled study evaluated the use of coenzyme Q<sub>10</sub> in women with breast cancer having adjuvant ChT.<sup>69</sup> Coenzyme Q<sub>10</sub> was used at doses of 100 mg three times daily (t.i.d.) in combination with vitamin E (100 mg for each dose of coenzyme Q<sub>10</sub>) for 24 weeks, without a difference in CRF.

**Wisconsin ginseng.** Several studies investigated the possible role of ginseng in the treatment of CRF. These trials are very heterogeneous, mainly due to the use of different kinds and doses of ginseng and to the variability of enrolled patients and type of cancers.

The double-blind, randomised, placebo-controlled, phase III trial on fatigued cancer survivor patients evaluated 2000 mg of Wisconsin ginseng (a common type of American ginseng) versus placebo for 8 weeks. CRF was evaluated by the general subscale of the Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) at baseline and at 4 and 8 weeks.<sup>70</sup> Three hundred and sixty-four participants undergoing or having undergone curative intent treatment were enrolled. A statistically significant difference was seen at 8 weeks, with greater benefit reported in patients receiving active cancer treatment versus those who had completed treatment. Toxicities did not differ significantly. The study included a heterogeneous population, with different neoplasms and different stages of disease.

**Other nutraceutical treatments.** Better planned studies are needed to define the role of astragalus, guarana and mistletoe in the control of CRF.

Astragalus, a flowering plant in the family Fabaceae, has been studied in a randomised trial in patients with advanced cancer showing a greater fatigue-improvement response rate compared with placebo.<sup>71</sup>

Guarana has been investigated in two randomised, placebo-controlled trials. The first one in patients with breast cancer undergoing ChT showed an improvement in

CRF<sup>72</sup>; the second one in patients with various solid tumours treated with ChT showed no difference compared with placebo.<sup>73</sup>

Mistletoe was administered as an aqueous extract in 352 breast cancer patients during ChT with cyclophosphamide, methotrexate and fluorouracil (CMF). The results showed an improvement in QoL, fatigue and other symptoms for mistletoe compared with placebo.<sup>74</sup>

Moreover, mistletoe extract has been evaluated in an open-label, randomised, phase III study in 220 patients with advanced pancreatic cancer receiving only best supportive care.<sup>75</sup> Mistletoe extract was given in escalating doses by subcutaneous injection t.i.d. The planned interim analysis indicated that mistletoe treatment was associated with longer overall survival (OS). Therefore, the trial was terminated prematurely as an improvement in QoL, fatigue and other symptoms with mistletoe was shown. However, the study has some shortcomings as there was no placebo control group and patients receiving mistletoe had more contact with the caregivers, which might indicate a more intensive supportive care therapy.

### Recommendations

- Concerning the use of Wisconsin ginseng, the panel has not reached a consensus:
  - for three panel members, extracts of Wisconsin ginseng could be considered for patients with fatigue and no other treatable reasons and where the fatigue lasts >4 weeks during active cancer treatment [II, C];
  - for the other six panel members, Wisconsin ginseng cannot be recommended [II, D].
- The use of L-carnitine, coenzyme Q<sub>10</sub>, astragalus and guarana is not recommended currently for the control of CRF [II, D].
- Concerning the use of mistletoe extracts, the panel has not reached a consensus:
  - for three panel members, mistletoe extracts could be considered for the control of fatigue in advanced pancreatic cancer [II, C];
  - for the other six panel members, mistletoe cannot be recommended [II, D].

### Psychosocial interventions

Psychosocial interventions for treating CRF cover a broad range of various interventions such as psychosocial counselling, psychotherapy or psychoeducation and mind-body interventions.<sup>76</sup> Apart from communicating information about CRF, the main goals of interventions are to help patients restructure their cognitive appraisal of CRF, change their coping strategies and behaviour and address self-help or self-care strategies. Some interventions include elements such as relaxation techniques, energy conservation and stress management. Most of the psychosocial interventions may be carried out as both individual and group interventions. Some of the psychosocial interventions are combined with physical activity or training.

**Information and counselling.** Information and counselling can help patients to gain a better understanding of CRF and see it not only as a result of cancer and its treatment but also as a condition influenced by various psychosocial factors. As a first step, information on the multifactorial nature of CRF and its potential causes and influencing factors should be given. Counselling can help the patients to devise a personalised activity plan, taking restrictions due to CRF into account. Counselling should include recommendations for energy preservation, task prioritisation, activity pacing and advice on how to delegate less important activities.<sup>77</sup>

There is some evidence showing that such strategies can improve QoL and reduce the subjective feeling of fatigue.<sup>77</sup> Information and counselling may be supported by brochures or interactive media, including internet platforms. Information and counselling should be provided not only for the individual patient but also for partners or family members, which can help prevent negative psychosocial implications, such as misunderstandings and emotional withdrawal.

**Psychoeducation.** Psychoeducational interventions focus on the management of CRF and help patients to promote self-management, adaptation and adjustment to their current condition and treatments. The most important goal of psychoeducational intervention is to facilitate self-care for the person with cancer.<sup>78</sup> Recognising that emotional distress is highly correlated with fatigue, psychoeducational interventions should focus on identification of coping strategies to optimise the patient's ability to deal with anxiety, depression and psychosocial distress.

It may be helpful for patients to identify sources of psychosocial distress and to eliminate stress-producing activities where possible. Another important element is to focus the patient's attention on the patterns of fatigue and on finding a balance between rest and activity during the day. This can be done by using diary techniques, including subjective rating of each activity in terms of the perceived level of fatigue. These techniques can be helpful for the patient to identify fatigue-promoting activities and develop specific strategies to avoid or modify these activities. It is important to support the patients in setting realistic goals to avoid frustration and to partake in self-restoring activities.<sup>79</sup> An individual activity/rest programme can be included, based on an assessment of the patient's fatigue patterns such as relaxation techniques or meditation, which may target underlying biological mechanisms and reduce cancer-related distress by diminishing activation of the hypothalamic pituitary adrenal (HPA) axis.<sup>80</sup> Outcomes of psychoeducational programmes have been investigated in several studies demonstrating a measurable reduction in CRF as well as an increase of vitality, with small to moderate effects on overall CRF.<sup>81,82</sup>

**Cognitive behavioural therapy.** Cognitive behavioural therapy (CBT) addresses emotions, behaviours and cognitive processes and applies them toward goal-oriented and systematic activities. CBT in CRF takes into account the

thoughts and functional behaviours relevant to the syndrome and focuses on the individual and their pattern of psychological factors.<sup>83</sup> CBT is generally used post-treatment and in the long term but may also be used for patients with acute fatigue still undergoing ChT.<sup>84</sup> CBT is generally used to address the following factors:

- coping with the experience of cancer;
- fear of disease recurrence;
- dysfunctional thoughts and beliefs regarding fatigue<sup>85</sup>;
- sleep dysregulation<sup>86</sup>;
- activity dysregulation<sup>77</sup>;
- low social support/negative social interactions.

There have been several studies on the evaluation of CBT, but fatigue has been investigated as the primary outcome in just a few of them.<sup>81,84,87</sup> In these studies, a clinically significant decrease in fatigue severity and functional impairment has been demonstrated.

### Mind-body interventions.

**Mindfulness-based stress reduction:** Mindfulness-based clinical interventions combine meditation exercises with psychoeducational elements, cognitive-behavioural interventions and movement exercises. The core practices are sitting meditation with breath awareness and focused attention, awareness of sensations in the body (body scan), yoga exercises (e.g. hatha yoga, mindful movement), walking meditation and insight meditation. The two most used mindfulness-based clinical interventions in oncology are mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT).

MBSR is a specific multimodal programme focused on improving well-being and health. It has been used as an intervention for cancer patients. A meta-analysis showed the effects of MBSR on the mental health of cancer patients (Cohen's effect size  $d = 0.18$ ).<sup>88</sup> Documented benefits after programme participation include improvements in:

- stress;
- mood;
- anxiety;
- depressive mood;
- sleep;
- fatigue;
- psychological functioning;
- psychosocial adjustment;
- stress reduction;
- enhancements in coping and well-being symptoms;
- QoL;
- fear of recurrence.<sup>89</sup>

Most of the studies do not specifically use CRF reduction as an outcome criterion, but a combination of the multiple health-related outcomes, including fatigue. However, studies have shown that MBSR may be helpful for improving CRF.<sup>90</sup> More prospective, randomised studies are needed to determine whether MBSR can be recommended for CRF.

**Yoga:** Yoga is a mind-body intervention comprising a combination of physical poses with a focus on breathing and meditation. There are several studies in which the benefits of yoga have been investigated in cancer patients, with most of these studies addressing multimodal outcome criteria, including fatigue.<sup>82</sup> In 2012, a systematic review and meta-analysis investigated the role of yoga<sup>91</sup>; a systematic review published in 2019 included a total of 29 RCTs.<sup>92</sup> Most studies showed that yoga compared with placebo improved overall QoL, fatigue and stress/distress during treatment.<sup>93</sup> Some studies found yoga had a moderate-to-high effect on decreasing fatigue severity.<sup>91,92</sup> Although patients practicing yoga may perceive improvements in QoL, there is a need for randomised controlled studies, especially on women with breast cancer.<sup>91–93</sup> Regarding cancer survivors, a phase III RCT compared the effect of yoga with standard survivorship care on CRF, and a significant benefit of yoga was reported.<sup>94</sup>

**Acupuncture:** After a pilot study demonstrating promising findings, several RCTs have been published on the role of acupuncture in the control of CRF. A meta-analysis including seven RCT studies, some with methodological flaws, has been published.<sup>95</sup> No recommendations have been suggested. More recently, another meta-analysis of 10 randomised clinical trials including 1327 patients (733 submitted to acupuncture and 594 to control) has been reported.<sup>96</sup> Acupuncture had a marked effect on fatigue in cancer patients, independently of concurrent anticancer treatment, particularly for breast cancer patients, but in six studies, adverse events have been reported. Furthermore, acupuncture was shown to reduce fatigue more than sham acupuncture or usual care. In conclusion, acupuncture sessions (20–30 minute sessions three times weekly for 2–3 weeks, twice weekly for 2 weeks and weekly for 6 weeks thereafter) have been suggested as efficacious for CRF.

### Recommendations

- Information and counselling are recommended in cancer patients and their caregivers to help them in understanding CRF and to educate them about ways to either prevent fatigue, avoid it becoming a chronic condition or to manage it [II, B].
- Psychoeducation is recommended to manage CRF [II, B].
- CBT is recommended to manage CRF [II, B].
- MBSR could be an option to improve CRF [II, C].
- Yoga could be an option to improve CRF in cancer survivors and QoL [II, C].
- Concerning the use of acupuncture, the panel has not reached a consensus:
  - for three panel members, it could be an option [II, C]
  - for the other six panel members, it cannot be recommended [II, D].

### Elderly cancer patients and CRF

Few data are available about fatigue in the elderly cancer patient (ECP; patients  $\geq 65$  years old), both for its evaluation and treatment.

Fatigue has a negative impact on patient-reported QoL and is frequently responsible for impaired activity and functional dependence in the ECP.<sup>97</sup> Very few studies have evaluated the prevalence of fatigue in the ECP.

In a review on elderly patients with head and neck cancer receiving cancer treatment, fatigue was reported in up to 60% of patients.<sup>98</sup> Other studies on American and Canadian elderly populations with different tumours reported a fatigue prevalence between 69% and 72%.<sup>99,100</sup>

The highest fatigue level in older cancer patients is reported in a retrospective cross-sectional study on 214 patients  $>70$  years old with different types of malignancies (breast cancer, non-Hodgkin lymphoma, prostate cancer, colorectal cancer and others); fatigue prevalence was 81%.<sup>97</sup> The difference in the reported fatigue prevalence in the studies mentioned above could be derived from the few data about ECPs or from the different ways fatigue is investigated (presence/absence or fatigue reported only if the intensity is  $\geq$  moderate). In the elderly patients, some comorbidity (anaemia, depression) and conditions (loss of lean mass, sarcopaenia) are correlated with fatigue.

### Screening and assessment

The approach to screening and scoring CRF in the ECP is the same as in adult cancer patients (see Figure 1). Because every clinical intervention can impact the fatigue status, it is necessary to repeat fatigue assessment. Cancer survivors can also experience fatigue so their fatigue status should be monitored.

There is no specific instrument to investigate or measure fatigue in elderly patients, but an NRS from 0 to 10 has been used in the elderly setting as an easy way to measure fatigue. In elderly patients, there is an increased risk of drug interaction due to polypharmacy and also a higher risk of potentially inappropriate medication. It is, therefore, very important that an inventory or review of all drugs taken by the patient is carried out during the fatigue assessment.<sup>101</sup>

### Management

In the elderly setting, the objective of CRF therapy is to maintain the patients' functional independence. The intervention on fatigue has to be tailored individually. Only an accurate report about patient history can identify the relevant issue that has to be treated.

Very little evidence about treatment in the ECP is available. No randomised, double-blind, placebo-controlled studies evaluating pharmacological treatments have specifically been carried out in the ECP. The same is true for nutraceutical treatments, physical exercise, psychosocial treatments and mind-body interventions. The only exception is a study evaluating the effect of a 4-week yoga intervention in older cancer survivors ( $\geq 60$  years of age) with fatigue. This study reported the results of a secondary analysis on data from a phase III RCT with two arms (standard care versus standard care and yoga). In 97 patients, yoga significantly reduced the CRF compared with standard care.<sup>102</sup>



## Recommendations

- Patient and family education is recommended to reduce fatigue and emotional distress [II, C].
- Physical activity including aerobic and resistance is recommended for the control of CRF [II, B].
- Psychosocial intervention (behavioural therapy, psychotherapy, support groups, changing coping strategies, relaxation, energy conservation, stress management) is recommended to improve fatigue in ECPs experienced during oncological treatment [II, C].
- Pharmacological interventions are not recommended for the control of CRF [II, D].

## METHODOLOGY

After a systematic search in several medical search engines (PubMed and ISI Web of Knowledge) of the terms 'Fatigue' and 'Cancer Related Fatigue', a total of 438 articles were found and selected by the expert authors. Some articles were eliminated for the following reasons: articles not specifically about CRF, articles not written in English, repeated articles or with no abstract available. These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development (<http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology>). The relevant literature has been selected by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in [supplementary Table S2](#), available at *Annals of Oncology* online.<sup>103</sup> Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty. This manuscript has been subjected to an anonymous peer review process.

## ACKNOWLEDGEMENTS

The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines.

## FUNDING

No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.

## DISCLOSURE

AF has reported advisory boards and/or honoraria for presentations for Roche, Pfizer, Lilly and Celgene; KJ has reported advisory boards and/or honoraria for presentations for Merck Sharp & Dohme, Merck, Amgen, Hexal, Reimser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-Med, PharmaMar, Prime Oncology and Onko Update; CIR has reported collaborations with Inpharm, Kyowa Kirin, Amgen Europe and Molteni Spa; RB, FR, SF, JW, MG and MVH have declared no potential conflicts of interest.

## REFERENCES

1. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatment. *Nat Rev Clin Oncol*. 2014;11:597–609.

2. Horneber M, Fischer I, Dimeo F, et al. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. *Dtsch Arztebl*. 2012;109:161–167.
3. Morrow GR. Cancer-related fatigue: causes, consequences, and management. *Oncologist*. 2007;12(Suppl 1):1–3.
4. Fabi A, Falcicchio C, Giannarelli D, et al. The course of cancer related fatigue up to ten years in early breast cancer patients: what impact in clinical practice? *Breast*. 2017;34:44–52.
5. Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. *Cancer*. 2002;95:2017–2026.
6. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PDL1 immune checkpoint antibodies. *Ann Oncol*. 2015;26:2375–2391.
7. Oxnard GR, Ramalingam SS, Ahn M, et al. Preliminary results of TATTON, a multiarm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. *J Clin Oncol*. 2015;33:15s.
8. Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. *Oncologist*. 2007;12(Suppl 1):22–34.
9. Barsevick AM, Irwin MR, Hinds P, et al. Recommendations for high-priority research on cancer-related fatigue in children and adults. *J Natl Cancer Inst*. 2013;105:1432–1440.
10. Cella D, Davis K, Breitbart W, Curt G. Fatigue coalition cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. *J Clin Oncol*. 2001;19:3385–3391.
11. ICD-11 (International Statistical Classification of Diseases and Related Health Problems, 11th Revision). Geneva, Switzerland: World Health Organization; 2019.
12. Donovan KA, McGinty HL, Jacobsen PB. A systematic review of research using the diagnostic criteria for cancer-related fatigue. *Psychooncology*. 2013;22:737–744.
13. Brown LF, Kroenke K. Cancer related fatigue and its associations with depression and anxiety: a systematic review. *Psychosomatics*. 2009;50:440–447.
14. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue*. Version 2. Fort Washington, PA: NCCN; 2018.
15. Howell D, Keshavarz H, Broadfield L, et al. *A Pan Canadian Practice Guideline for Screening, Assessment, and Management of Cancer-Related Fatigue in Adults Version 2*. Toronto: Education and Research Archive; 2015.
16. Fisher MI, Davies C, Lacy H, et al. Oncology Section EDGE Task Force on cancer: measures of cancer-related fatigue - a systematic review. *Rehabil Oncol*. 2018;36:93–105.
17. Given B, Given CW, Sikorskii A, et al. Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cutpoints? *J Pain Symptom Manage*. 2008;35:126–135.
18. Mendoza TR, Wang XS, Kugaya A, et al. The rapid assessment of fatigue severity in cancer patients; use of the Brief Fatigue Inventory. *Cancer*. 1999;85:1186–1196.
19. Minton O, Stone P. A systemic review of the scales used for the measurement of cancer-related fatigue (CRF). *Ann Oncol*. 2009;20:17–25.
20. Weis J, Tomaszewski KA, Hammerlid E, et al. International psychometric validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12). *J Natl Cancer Inst*. 2017;109(5):djw273.
21. Weis J, Wirtz MA, Tomaszewski KA, EORTC Quality of Life Group, et al. Sensitivity to change of the EORTC quality of life module measuring cancer-related fatigue (EORTC QLQ-Fa12): results from the international psychometric validation. *Psychooncology*. 2019;28(8):1753–1761.
22. Rudolf S, Bermejo I, Schweiger U, et al. Diagnostik depressiver Störungen. *Dtsch Arztebl*. 2006;103:A1754–A1762.
23. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. *JAMA Oncol*. 2017;1:961–968.

24. Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. *Am J Prev Med*. 2012;43:1–24.
25. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. *Cochrane Database Syst Rev*. 2012;15(8):CD007566.
26. NCCN clinical practice guidelines in oncology. Cancer-related fatigue. *J Natl Compr Cancer Netw*. 2010;8:904–931.
27. Jette M, Sidney K, Blumchen G. Metabolic equivalents (METs) in exercise testing, exercise prescription and evaluation of functional capacity. *Clin Cardiol*. 1990;13:555–565.
28. Burr JF, Jones LW, Shephard RJ. Physical activity for cancer patients. Clinical risk assessment for exercise clearance and prescription. *Can Fam Physician*. 2012;58:970–972.
29. Kampshoff CS, Chinapaw MJ, et al. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise after chemotherapy (REACT) study. *BMC Med*. 2015;13:275–281.
30. Brown J, Byers T, Doyle C, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices—American Cancer Society. *CA Cancer J Clin*. 2003;53:268–291.
31. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. *Cancer Treat Rev*. 2013;39:534–540.
32. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. *J Clin Oncol*. 2007;25:4396–4404.
33. Brown JC, Huedo-Medina TB, et al. Efficacy of exercise intervention in modulating cancer-related fatigue among adult cancer survivors: a meta analysis. *Cancer Epidemiol Biomarkers Prev*. 2011;20:123–133.
34. Van Waart H, Stuiver MM, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. *J Clin Oncol*. 2015;33:1918–1927.
35. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. *J Clin Oncol*. 2005;23:899–909.
36. Courneya KS, McKenzie DC, Mackey JR, et al. Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. *J Natl Cancer Inst*. 2013;105:1821–1832.
37. Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. *Cancer Pract*. 2001;9:119–127.
38. De Salles BF, Simao R, Miranda F, Novaes Jda S, et al. Rest interval between sets in strength training. *Sports Med*. 2009;39:765–777.
39. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc*. 2010;42:1409–1426.
40. Bruera E, Yennurajalingam S, Palmer JL, et al. Methylphenidate and/or nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. *J Clin Oncol*. 2013;31:2421–2427.
41. Bruera E, Valero D, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. *J Clin Oncol*. 2006;24:2073–2078.
42. Butler Jr JM, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. *Int J Radiat Oncol Biol Phys*. 2007;69:1496–1501.
43. Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. *Cancer*. 2010;116:5102–5110.
44. Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. *J Pain Symptom Manage*. 2012;43:68–77.
45. Richard PO, Fleshner NE, Bhatt JR, et al. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. *BJU Int*. 2015;116:744–752.
46. Mar Fan HG, Clemons M, Xu W, et al. A randomized, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. *Support Care Cancer*. 2008;16:577–583.
47. Mitchell GK, Hardy JR, Nikles CJ, et al. The effect of methylphenidate on fatigue in advanced cancer: an aggregated N-of-1 trial. *J Pain Symptom Manage*. 2015;50:289–296.
48. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. *J Pain Symptom Manage*. 2009;38:650–652.
49. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. *J Clin Oncol*. 2010;28:3673–3679.
50. Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. *Cancer J*. 2014;20:8–14.
51. Auret KA, Schug SA, Bremner AP, et al. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. *J Pain Symptom Manage*. 2009;37:613–621.
52. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. *Cancer*. 2010;116:3513–3520.
53. Boele FW, Douw L, de Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. *Neuro Oncol*. 2013;15:1420–1428.
54. Spathis A, Fife K, Blackhall F, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. *J Clin Oncol*. 2014;32:1882–1888.
55. Hovey E, de Souza P, Marx G, et al. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. *Support Care Cancer*. 2014;22:1233–1242.
56. Page BR, Shaw EG, Lu L, et al. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. *Neuro Oncol*. 2015;17:1393–1401.
57. Lee EQ, Muzikansky A, Drappatz J, et al. A randomized, placebo-controlled pilot study of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. *Neuro Oncol*. 2016;18:849–854.
58. Berenson JR, Yellin O, Shamasunder HK, et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. *Support Care Cancer*. 2015;23:1503–1512.
59. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *J Clin Oncol*. 2003;21:4635–4641.
60. Roscoe JA, Morrow JR, Hickok JT, et al. Effect of paroxetine hydrochloride (paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. *Breast Cancer Res Treat*. 2005;89:243–249.
61. Bruera E, El Osta B, Valero B, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. *J Clin Oncol*. 2007;25:3475–3481.
62. Yennurajalingam S, Frisbee-Hume S, Palmer L, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. *J Clin Oncol*. 2013;31:3076–3082.
63. Paulsen O, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. *J Clin Oncol*. 2014;32:3221–3228.

64. Dimsdale JE, Ball ED, Carrier E, et al. Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. *Support Care Cancer*. 2011;19:2015–2020.
65. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. *Cancer Prev Control*. 1998;2:74–78.
66. Lund Rasmussen C, Klee Olsen M, Thit Johnsen A, et al. Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: a double-blind placebo-controlled crossover trial. *Cancer*. 2015;121:3727–3736.
67. Cruciani RA, Zhang JJ, Manola J, et al. L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. *J Clin Oncol*. 2012;30:3864–3869.
68. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. *J Pain Symptom Manage*. 2009;37:622–631.
69. Lesser GJ, Case D, Stark N, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. *J Support Oncol*. 2013;11:31–42.
70. Barton DL, Liu H, Dakhil SL, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst*. 2013;105:1230–1238.
71. Chen HW, Lin IH, Chen YJ, et al. A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. *Clin Invest Med*. 2012;35:1–11.
72. de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. *J Altern Complement Med*. 2011;17:505–512.
73. del Giglio AB, Cubero Dde I, Lerner TG, et al. Purified dry extract of Paullinia cupana (guarana) (PC-18) for chemotherapy-related fatigue in patients with solid tumors: an early discontinuation study. *J Diet Suppl*. 2013;10:325–334.
74. Semiglazov VF, Stepula VV, Dudov A, et al. Quality of life is improved in breast cancer patients by standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. *Anticancer Res*. 2006;26:1519–1529.
75. Tröger W, Galun D, Reif M, et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. *Dtsch Arztl Int*. 2014;111:493–502.
76. Mustian K, Morrow G, Carroll J, et al. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. *Oncologist*. 2007;12:52–67.
77. Barsevick AM, Dudley W, Beck S, et al. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. *Cancer*. 2004;100:1302–1310.
78. Williams SA, Schreier AM. The role of education in managing fatigue, anxiety, and sleep disorders in women undergoing chemotherapy for breast cancer. *Appl Nurs Res*. 2005;18:138–147.
79. Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. *J Clin Oncol*. 2005;23:6027–6036.
80. Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. *J Clin Oncol*. 2005;23:6009–6018.
81. Bourmaud A, Anota A, Moncharmont C, et al. Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study. *Br J Cancer*. 2017;116:849–858.
82. Goedendorp MM, Gielissen MF, Verhagen CA, et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. *Cochrane Database Syst Rev*. 2009;(1):CD006953.
83. Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. *J Clin Oncol*. 2004;22:507–516.
84. Gielissen MF, Schattenberg AV, Verhagen CA, et al. Experience of severe fatigue in long-term survivors of stem cell transplantation. *Bone Marrow Transplant*. 2007;39:595–603.
85. Servaes P, Verhagen C, Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. *Ann Oncol*. 2002;13:589–598.
86. Prue G, Rankin J, Allen J, et al. Cancer related fatigue: a critical appraisal. *Eur J Cancer*. 2006;42:846–863.
87. Given BA, Given CW, Jeon S, et al. Effect of neutropenia on the impact of a cognitive-behavioral intervention for symptom management. *Cancer*. 2005;104:869–878.
88. Ledesma D, Kumano H. Mindfulness-based stress reduction and cancer: a meta-analysis. *Psychooncology*. 2009;18:571–579.
89. Shennan C, Payne S, Fenlon D. What is the evidence for the use of mindfulness-based interventions in cancer care? A review. *Psychooncology*. 2011;20:681–697.
90. Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. *J Natl Cancer Inst Monogr*. 2014;50:346–358.
91. Buffart L, van Uffelen JG, Riphagen I, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer*. 2012;12:559.
92. Danhauer SC, Addington EL, Cohen L, et al. Yoga for symptom management in oncology: a review of the evidence base and future directions for research. *Cancer*. 2019;125(12):1979–1989.
93. Cramer H, Lauche R, Klose P, et al. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database Syst Rev*. 2017;3:1.
94. Lin PJ, Kleckner IR, Loh KP, et al. Influence of yoga on cancer-related fatigue and on mediational relationships between changes in sleep and cancer-related fatigue: a nationwide, multicenter randomized controlled trial of yoga in cancer survivors. *Integr Cancer Ther*. 2019;18:1534735419855134.
95. Zeng Y, Luo T, Finnegan-John J, et al. Meta-analysis of randomized controlled trials of acupuncture for cancer-related fatigue. *Integr Cancer Ther*. 2014;13:193–200.
96. Zhang Y, Lin L, Li H, et al. Effects of acupuncture on cancer-related fatigue: a meta-analysis. *Support Care Cancer*. 2018;26:415–425.
97. Luciani A, Jacobsen PB, Extermann M, et al. Fatigue and functional dependence in older cancer patients. *Am J Clin Oncol*. 2008;31:424–430.
98. Maggiore R, Zumsteg ZS, Brintzenhopszoc K, et al. The older adult with locoregionally advanced head and neck squamous cell carcinoma: knowledge gaps and future direction in assessment and treatment. *Int J Radiat Oncol Biol Phys*. 2017;98:868–883.
99. Luctkar-Flude M, Groll D, Woodend K, et al. Fatigue and physical activity in older patients with cancer: a six-month follow-up study. *Oncol Nurs Forum*. 2009;36:194–202.
100. Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. *Crit Rev Oncol Hematol*. 2003;47:273–279.
101. Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. *J Am Geriatr Soc*. 2014;62:1505–1512.
102. Sprod LK, Fernandez ID, Janelins MC, et al. Effects of yoga on cancer-related fatigue and global side-effect burden in older cancer survivors. *J Geriatr Oncol*. 2015;6:8–14.
103. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. *Clin Infect Dis*. 2001;33(2):139–144 (Adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. *Clin Infect Dis*. 1994;18:421).